Monoclonal antibodies. Targeted treatment.
D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000918:Antibody Specificity; D000970:Antineoplastic Agents / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D001943:Breast Neoplasms / Q000188:drug therapy; D003424:Crohn Disease / Q000188:drug therapy; D006801:Humans; D000922:Immunotoxins / Q000276:immunology / Q000627:therapeutic use*; D000069285:Infliximab; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D018501:Antirheumatic Agents; D000922:Immunotoxins; C422802:ibritumomab tiuxetan; D000069285:Infliximab; D000068878:Trastuzumab